Earlier today, Vermillion announced the signing of a cooperative research and development agreement, CRADA, with the U.S. Army Medical Research and Materiel Command, USAMRMC. The two-phase study will investigate the cost-benefit profile of OVA1 testing as a presurgical standard of care in women with pelvic masses, and assess OVA1 clinical utility in a managed care setting. Thomas McLain, president and CEO of Vermillion, stated: "Our clinical collaboration with the U.S. Armed Forces is an important step towards OVA1 becoming a presurgical standard of care in women with pelvic masses. They are uniquely positioned to measure the total cost of care and medical outcomes across a large patient population in a standardized and rigorous manner." Vermillion shares rose 9% to $1.18 in mid-day trading following the announcement.